June 4, 2010

Agendia Presents Broad Array of Predictive and Prognostic Studies on Breast and Colorectal Cancers at ASCO 2010 Annual Meeting

HUNTINGTON BEACH, CA, and AMSTERDAM, THE NETHERLANDS, June 4, 2010 — Agendia, a world leader in molecular cancer diagnostics, today announced that researchers from Agendia and leading academic centers in the U.S. and Europe will present data from multiple studies concerning Agendia’s MammaPrint®, BluePrint™, and ColoPrint™ at the American Society of Clinical Oncology Annual Meeting, June 4 – 8, 2010, at McCormick Place in Chicago. MammaPrint, the company’s lead product, is the only FDA-cleared breast cancer recurrence test. FDA clearance requires clinical and analytical validation and full transparency to ensure patient safety issues are addressed. The company anticipates launching its prognostic colon cancer test ColoPrint in late 2010.
 
The study results underpin the broad predictive and prognostic power of MammaPrint and highlight prospective and independently validated data on ColoPrint. Visitors can meet the Agendia team in booth #18018 and study results will be discussed at the following sessions:
 
Breast Cancer
Date: Saturday, June 5, 2010
POSTER PRESENTATION – Abstract #10615
Substratification of 70-gene high-risk breast cancers with a validated 80-gene molecular subtyping profile
F. de Snoo, B. Chan, P. Roepman, R. A. Bender, A. Glas
 
Time: 8:00 AM – 12:00 PM
Location: S Hall A2
 
Date: Saturday, June 5, 2010
POSTER PRESENTATION – Abstract # 540
Gene signatures as predictors of response to neoadjuvant chemotherapy (NCT) with docetaxel, doxorubicin, cyclophosphamide (TAC), or AC and nab-paclitaxel (nab-P) and carboplatin ± trastuzumab in patients (pts) with stage II-III and inflammatory breast cancer (IBC)
G. Somlo, P. H. Frankel, L. Vora, S. Lau, T. H. Luu, L. Kruper, J. Yim, Y. Yen, F. de Snoo, R. A. Bender
 
Time: 2:00 PM – 6:00 PM
Location: S Hall A2
 
Date: Saturday, June 5, 2010
POSTER PRESENTATION – Abstract # 561
Evaluation of the 70-gene prognosis MammaPrint signature for the prediction of prognosis of breast cancer independently from histologic grade
M. Knauer, E. J. Rutgers, S. Mook, J. Wesseling, L. J. van ‘t Veer
 
Time: 2:00 PM – 6:00 PM
Location: S Hall A2
 
Date: Monday, June 7, 2010
POSTER DISCUSSION – Abstract # 1520
Effect of screening on the detection of good and poor prognosis breast cancers
Y. Shieh, L. Esserman, E. J. Rutgers, M. Knauer, V. Retel, S. Mook, A. Glas, S. C. Linn, F. E. van Leeuwen, L. van’t Veer
 
Time: 2:00 PM – 6:00 PM / 5:00 PM – 6:00 PM (discussion in E451b)
Location: E450b
 
Colon Cancer
Date: Monday, June 7, 2010
POSTER PRESENTATION – Abstract # TPS199
The PARSC trial, a prospective study for the assessment of recurrence risk in stage II colon cancer (CC) patients using ColoPrint
R. Salazar, J. Marshall, L. Stork-Sloots, I. Simon, M. Lutke Holzik, J. Tabernero, J. J. Van Der Hoeven, F. Bibeau, R. Rosenberg
 
Time: 8:00 AM – 12:00 PM
Location: S Hall A2
 
Date: Tuesday, June 8, 2010
POSTER DISCUSSION – Abstract # 3513
Independent validation of a prognostic genomic profile (ColoPrint) for stage II colon cancer (CC) patients
R. Rosenberg, M. Maak, U. Nitsche, T. Schuster, B. Kuenzli, M. Snel, I. Simon, K. Janssen, H. Friess
 
Time: 11:00 AM – 12:00 PM
Location: S 406 (Vista Room)
 
About MammaPrint®
MammaPrint is the first and only breast cancer recurrence test cleared by the U.S. Food and Drug Administration (FDA). FDA clearance under the in vitro diagnostic multivariate index assay (IVDMIA) guidelines requires clinical and analytical validation and reporting systems to ensure patient safety issues are addressed. Highly accurate, MammaPrint identifies patients with early metastasis risk — patients who are likely to develop metastases within five years following surgery. Several authoritative studies have shown that chemotherapy particularly reduces early metastasis risk. In planning treatment, the MammaPrint test results provide doctors with a clear rationale to assess the benefit of chemotherapy in addition to other clinical information and pathology tests.
 
All MammaPrint tests are conducted in Agendia’s CAP-accredited and CLIA compliant service laboratories.
 
About Agendia
Agendia is at the forefront of the personalized medicine revolution, striving to bring more effective, individualized treatments within reach of patients. Building on a cutting-edge genomics platform for tumor gene expression profiling, the company’s tests help physicians more accurately tailor cancer treatments. Agendia markets four products, with several new genomic tests under development. In addition, Agendia collaborates with pharmaceutical companies to develop highly effective personalized drugs in the area of oncology. Agendia is based in Huntington Beach, California, and in Amsterdam, The Netherlands.
 
 
MEDIA CONTACTS:
Hans Herklots
Agendia
+31.20.462.1557 Office
+31.620.083.509 Mobile
[email protected]
 
Valerie Delva
Ricochet Public Relations
+1.212.679.3300 x128 Office
+1.917.755.6194 Mobile
[email protected]